New hope for tough leukemia: drug combo targets hidden cancer cells

NCT ID NCT05146739

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 39 times

Summary

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps cancer cells hide in the bone marrow, making chemotherapy more effective. The main goal is to find the safest dose and understand how the drug works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

    Houston, Texas, 77030, United States

  • C S Mott Children's Hospital

    Ann Arbor, Michigan, 48109, United States

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia, 30329, United States

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Alabama

    Birmingham, Alabama, 35233, United States

  • Children's Hospital of Orange County

    Orange, California, 92868, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania, 15224, United States

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois, 60611, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Riley Hospital for Children

    Indianapolis, Indiana, 46202, United States

  • Saint Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • UCSF Medical Center-Mission Bay

    San Francisco, California, 94158, United States

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute myeloid leukemia mixed phenotype acute leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes myeloid leukemia associated with down syndrome therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.